Genmab A/S (CPH:GMAB)
Denmark flag Denmark · Delayed Price · Currency is DKK
3,912.00
+124.00 (3.27%)
Oct 30, 2026, 5:00 PM CET

Genmab Revenue

Genmab had revenue of $1.16B USD in the quarter ending June 30, 2026, with 24.86% growth. This brings the company's total for the last twelve months to $4.13B, up 28.86% year-over-year. In the year 2025, Genmab had annual revenue of $3.72B with 19.19% growth. That makes Genmab the 3,058th largest company in the world by revenue and 16th in Denmark.

Revenue (ttm)
$4.13B
Revenue Growth
+28.86%
P/S Ratio
8.65
Revenue / Employee
$1.32M
Employees
3,119
Market Cap
233.76B DKK

Revenue Chart

* This company reports financials in USD.

Revenue by Segment

By Segment

Chart
  • DARZALEX Royalties 2.44B 65.7%
  • Kesimpta Royalties 443.00M 11.9%
  • Net Product Sales 398.00M 10.7%
  • Other Product Royalties 111.00M 3.0%
  • TEPEZZA Royalties 105.00M 2.8%
  • Milestone 97.00M 2.6%
  • Collaboration 70.00M 1.9%
  • Reimbursement 53.00M 1.4%

By Geography

Chart
  • Denmark 3.33B 89.4%
  • Japan 213.00M 5.7%
  • United States 180.00M 4.8%
  • Netherlands 1.00M 0.0%
Fiscal year ended Dec 31, 2025 See the full Genmab breakdown

Revenue History

Fiscal Year EndRevenueChangeGrowth
Dec 31, 20253.72B599.00M19.19%
Dec 31, 20243.12B731.00M30.59%
Dec 31, 20232.39B302.26M14.48%
Dec 31, 20222.09B800.56M62.19%
Dec 31, 20211.29B-372.56M-22.45%
Dec 31, 20201.66B854.43M106.10%
Dec 31, 2019805.32M340.75M73.35%
Dec 31, 2018464.57M83.44M21.89%
Dec 31, 2017381.13M123.38M47.87%
Dec 31, 2016257.75M92.65M56.12%
Dec 31, 2015165.10M26.80M19.38%
Dec 31, 2014138.30M15.94M13.02%
Dec 31, 2013122.37M36.66M42.78%
Dec 31, 201285.70M24.59M40.23%
Dec 31, 201161.12M-43.27M-41.45%
Dec 31, 2010104.39M-8.77M-7.75%
Dec 31, 2009113.16M-16.25M-12.56%
Dec 31, 2008129.42M25.30M24.29%
Dec 31, 2007104.12M80.20M335.29%
Dec 31, 200623.92M8.33M53.41%
Dec 31, 200515.59M--

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.

Related Stocks

Company NameRevenue
Novo Nordisk329.43B
Coloplast28.44B
H. Lundbeck25.96B
Demant24.63B
GN Store Nord16.46B
ALK-Abelló6.83B
Embla Medical6.56B
Bavarian Nordic6.34B
Revenue Rankings